Anew Labs is developing experimental medicines with AI models and laboratory research. Its drug-discovery researchers use separate systems to predict biomolecular structures, examine how proteins and drug candidates move, and generate molecules intended to bind selected targets. The company’s public materials position those capabilities as infrastructure for its own drug pipeline, while making some research tools available through web interfaces. Reuters reported that the Shanghai-based ByteDance spinout completed a $290 million first external financing at a $1.5 billion valuation.
AnewOmni provides one concrete example of how researchers can use the technology. For a target-specific binder-design task, the model represents amino acids or molecular fragments as all-atom blocks, compresses them into a lower-dimensional representation, generates prospective binder structures and reconstructs their atomic details and chemical bonds. Anew reports testing generated small molecules, peptides and antibodies in binding or cellular assays. Those case studies illustrate AnewOmni’s workflow; they do not establish that every company program follows the same route.
Other Anew models address different parts of drug research. AnewFold predicts structures and potential binding pockets in biomolecular complexes. AnewSampling generates ensembles of protein and protein-ligand conformations, giving researchers a way to examine molecular motion and potentially important states during lead optimization without relying exclusively on costlier molecular-dynamics simulations. Anew presents these as adjacent capabilities, but its public pages do not document a mandatory sequence connecting every model.
The company says its broader platform spans target identification through clinical development. Its disclosed pipeline contains four programs: IL-17 and IL-4R candidates plus two undisclosed targets. Anew said it presented orally bioavailable IL-17 inhibitors at scientific meetings in April and June, including potency and in-vivo findings. Those are company-reported research results, not evidence of an approved medicine or completed human trial. Anew’s public materials center the business on an internal drug pipeline; although some tools have public interfaces, the pages do not describe paid access.
Reuters said HSG, IDG Capital and Hillhouse Investment led the financing, with 5Y Capital as a co-lead. Gaorong Ventures, Primavera Venture Partners, Boyu Capital, SBP Group and the Shanghai Future Industries Fund also participated, according to the report. ByteDance and the investors did not comment, and Reuters’ sources said ByteDance would retain a 56% stake after the transaction. The financing therefore remains reported rather than company-confirmed.
Reuters reported that ByteDance separated Anew because drug discovery operates differently from its core internet businesses. The financing gives the laboratory a dedicated capital base while leaving ByteDance in majority control. The operating question is whether Anew can move its company-reported research into human testing—and whether it will develop resulting medicines independently, through pharmaceutical partnerships or through another commercial model.